Cleveland Clinic Innovations – Creating A Global Innovation Engine

At a time when venture capital dollars are scarce and US-based innovation is threatened, Cleveland Clinic Innovations, with its novel GCIC cardiovascular project, is bringing critical mass and a new direction to an inherently unwieldy process.

At a recent medical device conference, a prominent physician from a large academic medical center called tech transfer, as it’s traditionally practiced at most academic centers “an arcane process that takes forever and generates very little.” Indeed, he went on, too often tech transfer programs are “a major obstacle to good ideas.” Most tech transfer executives are “way overworked and way underpaid with too much on their plates.” Worse, he went on, doctors today frequently grow “paranoid and become unwilling to share their ideas” with their tech transfer offices. “I’m willing to bet that there are a lot of good ideas just lying around,” he concluded, because of the inherent difficulties and frustrations physicians face in working with tech transfer offices.

He’s far from alone. All over the country, physician/inventors bemoan the state of tech transfer, charging that offices designed largely...

More from Innovation

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.